Furthermore, these studies used either experimental compounds (e.g., 4–4-dimethylaminostyryl-N-methylpyridinium (ASP+) and MPP+) or non-cancer drugs (e.g., metformin) as substrates, which may not be suitable to predict pOCT-mediated ALK drug interactions due to substrate-dependent inhibition. This evidence concerns the gene ALK and cancer.